Of note, we show that CRP kinetics can provide prognostic information in patients receiving immunotherapy independent of PDL-1 status and NSCLC histology and could thus be easily integrated in everyday clinical care. This evidence concerns the gene CD274 and non-small cell lung carcinoma.